Document Detail


Is interferon-beta an alternative treatment for chronic hepatitis C?
MedLine Citation:
PMID:  16718760     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The treatment of chronic hepatitis C (CHC) is still far from optimal, particularly for those subpopulations that do not respond to the standard combination therapy with Interferon-alpha (IFNalpha) plus ribavirin. Although in some cases the use of higher doses or longer treatment periods may be effective, these approaches are generally associated with a higher incidence of adverse events, which may either lead to a reduction in patient compliance or require drug withdrawal. IFNbeta could represent an interesting alternative for treating CHC patients. Controversial data about IFNbeta efficacy in CHC exist, the main reason being that many results stem from pilot studies with small cohorts of patients. However, promising results have been obtained in some subgroups of patients that fail to respond to IFNalpha. Additionally, the good tolerability of IFNbeta represents an important advantage of the drug. The rates of dropouts in controlled clinical trials, as well as the need for dose reductions or treatment discontinuation are very low. It might be worth assessing the value of IFNbeta plus ribavirin in randomized studies with a larger cohort of patients, not eligible or not tolerating standard therapy, and for non-responders.
Authors:
Ricardo Moreno-Otero; María Trapero-Marugán; Elena Gómez-Domínguez; Luisa García-Buey; José A Moreno-Monteagudo
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  World journal of gastroenterology : WJG     Volume:  12     ISSN:  1007-9327     ISO Abbreviation:  World J. Gastroenterol.     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-05-23     Completed Date:  2006-07-03     Revised Date:  2014-09-09    
Medline Journal Info:
Nlm Unique ID:  100883448     Medline TA:  World J Gastroenterol     Country:  China    
Other Details:
Languages:  eng     Pagination:  2730-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antiviral Agents / adverse effects,  therapeutic use*
Drug Therapy, Combination
Drug Tolerance
Hepatitis C
Hepatitis C, Chronic / drug therapy*
Humans
Interferon-alpha / therapeutic use
Interferon-beta / adverse effects,  therapeutic use*
Randomized Controlled Trials as Topic
Ribavirin / therapeutic use
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon-alpha; 49717AWG6K/Ribavirin; 77238-31-4/Interferon-beta
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A concomitant review of the effects of diabetes mellitus and hypothyroidism in wound healing.
Next Document:  Splenic vasculopathy in portal hypertension patients.